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Predictors of warfarin use in patients with non-valvular atrial
fibrillation who presented to the cardiology outpatient clinic of
a tertiary hospital in Turkey: an observational study
Faruk ERTAŞ, Hasan KAYA, Zuhal ARITÜRK ATILGAN, Mehmet Ali ELBEY, Mesut AYDIN,
Mehmet Ata AKIL, Mustafa OYLUMLU, Mehmet Sıddık ÜLGEN

Aim: The aim of this study was to investigate the predictors of warfarin use in patients with non-valvular atrial fibrillation
(AF). This study was the first to be conducted in a Turkish population.
Materials and methods: Patients who presented to our outpatient clinic with the diagnosis of AF between September
2008 and October 2009 were enrolled. The patients were classified according to the CHADS2 risk scoring system
recommended by the AHA/ACC/ESC guidelines for the classification of stroke risk in non-valvular AF patients. The
probable variables influencing the use of warfarin were determined as age, sex, income level, healthcare coverage,
lifestyle, place of residence, classification of AF, hypertension, diabetes mellitus, coronary artery disease, thyrotoxicosis,
cardiac insufficiency, left ventricular dysfunction, stroke risk stratification, and history of stroke or systemic embolism
(SE).
Results: Among the 570 patients enrolled in the study, 144 were excluded because of insufficient patient information
or refusal to participate, while 101 patients were excluded due to valvular AF. Thus, the evaluation was based on 325
patients (133 males and 192 females; mean age: 65 ± 10). According to the CHADS2 scoring, 62.2% of the patients
were at high risk, 26.8% were at moderate risk, and 11.1% were at low risk. Only 19.7% of the patients were on warfarin
treatment. In the logistic regression analysis, a history of stroke or SE, high income level, and the presence of persistent
and permanent AF were found to be positive predictors of warfarin use, while advanced age was a negative predictor of
warfarin use.
Conclusion: This study demonstrated that a history of stroke or SE, high income level, presence of persistent and
permanent AF, and advanced age are independent predictors of warfarin use in non-valvular AF patients.
Key words: Atrial fibrillation, warfarin, CHADS2, stroke, predictor

Introduction
Atrial fibrillation (AF) is a supraventricular
tachyarrhythmia frequently observed in clinical
practice and its prevalence increases with advancing
age. Thromboembolic events constitute an important
part of the morbidity and mortality associated with
AF. Stroke is the leading thromboembolic event
caused by AF (1–6), and the annual risk of stroke
in these patients varies between 3% and 8% (7).

Studies have shown that the most effective method
in preventing this serious complication of AF is
efficient anticoagulation achieved with warfarin
(8). In a number of randomized and controlled
studies, warfarin treatment at the target levels has
been demonstrated to reduce the risk of stroke by
two-thirds in patients with AF (9). Almost all the
studies demonstrating the relationship between atrial
fibrillation and warfarin treatment and evaluating the
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independent variables influencing the use of warfarin
have been conducted on western populations. To
date, no study has been conducted in this country
focusing on the association between AF, which affects
a major patient population and may lead to dramatic
outcomes like thromboembolytic complications, and
the predictors influencing the use of warfarin, which
has a demonstrated efficiency in preventing these
complications.
In the present study, our aim was to prospectively
investigate the frequency and predictors of warfarin
use in patients diagnosed with non-valvular AF
according to the recommendations of the AHA/
ACC/ESC AF guidelines. Since this study is the first
to be based on a Turkish population, we are of the
opinion that it will contribute to the literature in
this country and pave the way for the future studies
focusing on this point.
Materials and methods
Study population
The study group consisted of 570 consecutive
patients who presented to our cardiology outpatient
clinic with the diagnosis of AF between September
2008 and October 2009. Patients with prosthetic
valves or a history of rheumatic valvular disease,
those with contraindications against warfarin
treatment, and patients who refused to participate in
the study or supplied insufficient information were
excluded. Each patient was given information about
the purpose of the study and signed an informed
consent form. The approval of the ethics committee
was obtained before the start of the study. Patient
information was obtained either from the patients or
first-degree relatives.
Stroke risk stratification
Patients were classified according to the CHADS2
(congestive heart failure [CHF], hypertension
[HT], age ≥75, diabetes mellitus [DM], and prior
stroke or TIA) scoring system recommended by the
AHA/ACC/ESC atrial fibrillation guidelines for the
stratification of the risk in non-valvular AF.
Probable variables influencing warfarin use
From the medical records and the patient histories,
the probable variables thought to influence warfarin
use were specified as age, sex, income level,

healthcare coverage, lifestyle, place of residence,
classification of AF, HT, DM, coronary artery
disease (CAD), thyrotoxicosis, cardiac insufficiency
(CI), left ventricular (LV) dysfunction, stroke risk
stratification, and history of stroke or systemic
embolism (SE). In terms of the classification of AF,
patients were grouped as those with paroxysmal or
persistent/permanent AF. In terms of the stroke risk
stratification, patients were divided into 3 categories
as high risk, moderate risk, and low risk patients
based on the CHADS2 scoring. The determination
of the income level was based on the minimum
wage during the years the study was conducted. The
healthcare coverage of the patients was grouped in 4
categories according to the healthcare system in this
country comprising the Green Card, Social Insurance
Institution, State Retirement Fund, and the Social
Security Organization of Artisans and Self-Employed
Individuals. The lifestyle parameter was classified as
those who live together with their families and those
who live alone. The place of residence was described
as the urban area at the center of the province the
study was conducted in and the rural parts of the
same province. Patients were also asked about
any antiaggregant (aspirin) and/or anticoagulant
(warfarin) treatments.
Electrocardiography/echocardiography
All the patients enrolled in the study underwent
surface electrocardiography during the enrollment
phase through a 12-lead electrocardiography device
at a velocity of 25 mm/s and a calibration of 10
mm/mV. Moreover, in order to evaluate the LV
functions of the patients, 2-dimensional M-mode
echocardiographies were performed using a General
Electric-Vivid 3 echocardiography device.
Statistical analysis
Statistical analyses were performed using SPSS
(Statistical Package for the Social Sciences for
Windows) 15.0 software. Numerical variables
were evaluated through Student’s t-test, while the
categorical variables were compared using Pearson’s
chi-square test. A binary logistic regression analysis
was performed to evaluate the independent predictive
values of the potential variables of age, stroke, high
income level, and classification of AF as predictors of
warfarin use. Statistical significance was based on a
value of P < 0.05.
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Results
Among the 570 patients enrolled in the study,
144 were excluded because of insufficient patient
information or refusal to participate, while 101
patients were excluded due to valvular AF. Thus,
the evaluation was based on 325 patients (133 males
[40.9%] and 192 females [59.1%]; mean age: 65 ± 10).
The demographic and socioeconomic parameters of
the patient groups on warfarin treatment and those
who did not receive any warfarin treatment are
presented in Tables 1 and 2. The sex, age distribution,
and clinical risk factors of the patient groups were
similar. Only the warfarin treatment rate in patients
with a history of stroke or SE (P = 0.001) and in

those with persistent/permanent AF (P = 0.024) was
significantly higher. According to the CHADS2 score,
62.2% of the patients were in the high risk group,
26.8% were in the moderate risk group, and 11.1%
were in the low risk group. However, no difference was
observed between the groups in relation to warfarin
use. While no difference between the groups was
found in terms of the socioeconomic factors such as
healthcare coverage, lifestyle, and place of residence,
the rate of warfarin use was observed to increase with
increasing level of income (P = 0.002).
The treatment modalities administered to the
patients are presented in the Figure. Among the
patients, 56 (17.2%) were on aspirin and warfarin, 8

Table 1. Comparison of the patients on warfarin treatment with those not on warfarin in terms of clinical risk factors.
Warfarin (–)
(n = 261)

Warfarin (+)
(n = 64)

n (%)

n (%)

Male

108 (81.2)

25 (18.8)

Female

153 (79.7)

39 (20.3)

≤65

85 (75.2)

28 (24.8)

66–74

72 (80.0)

18 (20.0)

≥75

104 (85.2)

18 (14.8)

Main features

Sex

Age

Hypertension
Coronary artery disease
Cardiac insufficiency
LV dysfunction (EF)
Diabetes mellitus
History of stroke or
systemic embolism
Thyrotoxicosis
AF classification

Stroke risk stratification

1174

No

67 (82.7)

14 (17.3)

Yes

194 (79.5)

50 (20.5)

No

189 (78.8)

51 (21.2)

Yes

72 (84.7)

13 (15.3)

No

216 (80.9)

51 (19.1)

Yes

45 (77.6)

13 (22.4)

≤35%

41 (82.0)

9 (18.0)

>35%

220 (80.0)

55 (20.0)

No

220 ( 80.6)

53 (19.4)

Yes

41 (78.8)

11 (21.2)

No

230 (83.3)

46 (16.7)

Yes

31 (63.3)

18 (36.7)

No

246 (80.4)

60 (19.6)

Yes

15 (78.9)

4 (21.1)

Persistent/permanent

165 (76.7)

50 (23.3)

Paroxysmal

96 (87.3)

14 (12.7)

Mild

31 (86.1)

5 (13.9)

Moderate

73 (83.9)

14 (16.1)

High

157 (77.7)

45 (22.3)

P

0.736

0.154

0.529
0.235
0.565
0.744
0.772
0.001
0.878
0.024

0.311
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Table 2. Comparison of the patients on warfarin treatment with those not on warfarin in terms of socioeconomic parameters.
Warfarin (–)

Warfarin (+)

Socioeconomic factors

Income level

Healthcare coverage

Lifestyle

22 (13.9)

108 (78.3)

30 (21.7)

17 (58.6)

12 (41.4)

Green Card

60 (88.2)

8 (11.8)

Social Insurance Institution

121 (78.6)

33 (21.4)

Social Security Organization of Artisans and
Self-Employed Individuals

45 (76.3)

14 (23.7)

State Retirement Fund

29 (78.4)

8 (21.6)

With the family

231 (79.7)

59 (20.3)

Alone

30 (85.7)

5 (14.3)

Urban

185 (79.4)

48 (20.6)

Rural

76 (82.6)

16 (17.4)

Medication
Warfarin
Warfarin+ASA
ASA
None

80%

60%

40%

20%

Figure.

n (%)

136 (86.1)

100%

High risk
n = 202

n (%)
0–457 TL/month
(Low)
457–916 TL/month
(Moderate)
>916 TL/month
(High)

Place of residence

0%

P

Moderate risk
Low risk
n = 87
n = 36
Stroke risk stratification

Distribution of treatment used according to the risk
classification.

0.002

0.299

0.395

0.512

(2.5%) were only on warfarin, and 209 (64.3%) were
treated only with aspirin. The remaining 52 (16%)
patients were not on any of these treatment options.
From the point of view of the stroke risk category, the
rate of warfarin treatment in the high and moderate
risk groups was 22.3% and 16.1%, respectively.
Approximately one-tenth (10.4%) of the patients in
the high risk group and one-fourth of the patients in
the moderate risk group (26.8%) had not received any
of the warfarin and/or aspirin treatment modalities.
In the binary logistic regression analysis where
the factors affecting warfarin use were evaluated,
persistent/permanent AF, history of stroke or SE,
and high income level were found to be positive
predictors of warfarin use, while advanced age was
found to be a negative predictor (Table 3).
Discussion
This study demonstrates that although it is known that
the most efficient method to prevent an important
1175
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Table 3. Predictors of warfarin use in the multivariate regression analysis.
Clinical variables

Odds ratio

95% Confidence interval

P-value

Advanced age (>75)

0.410

0.201–0.835

0.014

Persistent/permanent AF

2.109

1.043–4.263

0.038

History of stroke or systemic embolism

2.912

1.418–5.979

0.004

High income level

4.338

1.757–10.711

0.001

complication
like
ischemic
cerebrovascular
diseases that develop secondary to AF is effective
anticoagulation provided by warfarin, AF patients in
this country do not receive adequate anticoagulative
treatment through warfarin in spite of the observed
indication. Furthermore, this study has indicated
that a history of stroke or SE, high income level, and
persistent/permanent AF are positive predictors of
warfarin use in patients with AF, while advanced age
is a negative predictor.
Several previous studies have demonstrated
that treatment with oral anticoagulants is effective
in preventing strokes and deaths related to
thromboembolism in patients with non-valvular
AF (10–15). The first large-scale study providing
data on oral anticoagulant treatment in patients
with AF was by Stafford and Singer (16). Warfarin
treatment was also previously studied in the Atrial
Fibrillation, Aspirin and Anticoagulation (17), Stroke
Prevention in Atrial Fibrillation (18–20), Boston
Area Anticoagulation Trial for Atrial Fibrillation
(21), Canadian Atrial Fibrillation Anticoagulation
(22), and Stroke Prevention in Nonrheumatic Atrial
Fibrillation (23) studies. When the results obtained
from these studies were examined in light of the
guidelines, a drastic increase was observed in the
number of the AF patients who received warfarin
treatment (10).
The most interesting studies on the predictors of
warfarin use in non-valvular AF patients are those
by Go et al. (12). Other investigators analyzed the
positive and negative predictors of warfarin use in
non-valvular AF patients (24–27). These studies
revealed that a history of stroke or SE and advanced
age are independent predictors of warfarin use (28).
In parallel to these studies, also in our study, a history
of stroke or SE and advanced age were observed to
1176

be independent predictors of warfarin use. However,
although the frequency of AF and the related stroke
risk increase in parallel with age, advanced age in
our study turned out to be an unexpected negative
predictor of warfarin use. We attributed this result to
the concerns of the physicians in this country related
to increased bleeding risk in the elderly. Moreover, in
the study by Go et al., socioeconomic factors (such
as income level, healthcare coverage, and lifestyle)
and place of residence (like urban or rural areas)
directly influencing the patients’ living conditions
were not evaluated. Our study revealed that high
income level is a positive predictor of warfarin use,
and, to the best of our knowledge, this point was not
investigated in the literature before. As the income
level increases, the individuals’ health knowledge and
their tendency to seek health assistance increase in
parallel. However, lifestyle and the place of residence
were observed to be unrelated to oral anticoagulant
treatment. It was especially surprising that the
place of residence did not have any influence on
oral anticoagulant treatment, since the general idea
is that oral anticoagulant use is rarer in patients
living in rural areas since the prothrombin time
cannot be checked frequently enough. The results
we observed may be related to the increase in the
number and equipment of the health centers in rural
areas and in the awareness of the patients in terms of
cardiovascular health in recent years.
Furthermore, except for the study by Waldo et
al. focusing on the predictors of oral anticoagulant
therapy (29), the classification of AF has not been
investigated as a predictor of warfarin use. It was
Waldo et al. who first suggested that persistent/
permanent AF was a positive predictor of warfarin use
(29). In agreement with their study, in our study the
presence of persistent/permanent AF was also shown

F. ERTAŞ, H. KAYA, Z. ARITÜRK ATILGAN, M. A. ELBEY, M. AYDIN, M. A. AKIL, M. OYLUMLU, M. S. ÜLGEN

to be a positive predictor of warfarin use. To the best
of our knowledge, this is the second study evaluating
this point. Although patients with paroxysmal AF
are at similar risk of stroke as persistent/permanent
AF patients, it is surprising that warfarin use is less
common in these patients. This may be associated
with both the physicians’ inadequate awareness of
paroxysmal AF and the fact that the patients regard
this situation as a transient disorder and are unwilling
to undergo a distressing process involving frequent
prothrombin time checks.
Interestingly enough, high risk of stroke was not
revealed to be an independent predictor for warfarin
use in spite of the slight tendency observed. Similarly,
in a study by McCormick et al. (30) conducted in
long-term care patients, as the number of the risk
factors for stroke increased, warfarin use also showed
an increasing trend, although this increase was
statistically insignificant. Data obtained from the
recent studies focusing on the subject also support
this point (31,32). The results of both studies show that
the stroke risk stratification is not paid due attention
by physicians and patients are not adequately warned
about this point.
In our study, 22.3% and 16.1% of the patients in the
high and moderate risk categories for stroke received
oral anticoagulant therapy, respectively. Although the
ACC/AHA/ESC joint guidelines recommend aspirin
treatment in addition to warfarin for the group at
moderate risk of stroke, only 14.9% of the patients
in the moderate risk group in our study had received
aspirin and warfarin in combination. In addition,
while the guidelines recommend only aspirin
treatment for the group at mild risk of stroke, 13.9%
of these patients in our study had received treatment
with the combination of aspirin and warfarin. These
results indicate that oral anticoagulant treatment
is not administered appropriately even in tertiary
hospitals in this country.
Since nearly all of the studies to date focusing
on the use of warfarin in AF patients have been
conducted on western populations, the obtained
results may show important differences from the
Turkish population. As our study is the first to be
conducted on this particular subject in this country,
we are of the opinion that our results reveal the real
characteristics of our society. For instance, previous

large-scale AF studies have indicated that age is
a primary predictor for AF. The ACC/AHA/ESC
guidelines developed based on these studies mostly
conducted in western societies consider age of 75
and above as a moderate risk factor and age of 65 and
above as a mild risk factor for stroke. It is known that
the average life expectancy in our society is lower
than that in western societies. Indeed, the majority
of the AF patients in our study were aged 65 years or
above, and their mean age was 65. For this reason,
drawing the line for the moderate risk factor at >65
years instead of >75 years may be considered when
the risk factors for ischemic stroke in the AF patients
in this country are determined.
The majority of the AF patients who presented to
the cardiology outpatient clinic of our hospital were
at high risk for ischemic stroke. In spite of the studies
that may be considered milestones in showing
the importance of oral anticoagulant therapy in
preventing strokes, only one-fifth (22.3%) of the
patients at high risk of stroke were receiving treatment
with oral anticoagulants. In this study reflecting daily
clinical practice, it is obvious that the inadequate use
of oral anticoagulant treatment modalities cannot
be explained just by medical contraindications. We
are of the opinion that the most important factor
leading to inadequate oral anticoagulant therapy is
the inadequate prescription by the physicians. The
observed lack of oral anticoagulant therapy reveals
that the guidelines are not efficiently reflected in
clinical practice. A possible reason for this may be
the fact that the majority of physicians organizing
the treatment for AF are not cardiologists. Moreover,
the majority of the physicians are not sufficiently
informed about AF and its risks, and are hesitant
about prescribing oral anticoagulant treatment.
These factors consequently tip the scale against the
oral anticoagulant therapy in terms of the risk/benefit
ratio.
In conclusion, we have demonstrated in this
study that the presence of persistent/permanent AF,
a history of stroke or SE, and high income levels
are positive independent predictors for warfarin
use, while advanced age is a negative independent
predictor. In this respect, awareness programs are
needed for both the physicians and the patients with
low income status, with paroxysmal AF, or at high risk
for stroke and not on adequate warfarin treatment.
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Since the present study is the first to be conducted
in the Turkish population, we are of the opinion that
it will contribute to the literature in this country
and pave the way for future studies focusing on this
point, so that the health community gains awareness
of AF patients, constituting a considerable patient
population in this country.

Limitations of the study
The main limitation of this cross-sectional study was
the limited number of study subjects.
This was a single-center study; therefore, its results
may not be generalized to other clinical settings.
Another limitation is the lack of HAS-BLED and
CHADS-VASc scores. A final limitation of our study
is that the patients were evaluated in a single visit and
no follow-up visits were conducted.
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